Sorafenib inhibits p38α activity in colorectal cancer cells and synergizes with the DFG-in inhibitor SB202190 to increase apoptotic response

References

• Chiacchiera F, Simone C. Signal-dependent regulation of gene expression as a target for cancer treatment: inhibiting p38alpha in colorectal tumors. Cancer Lett 2008; 265:16 - 26; http://dx.doi.org/10.1016/j.canlet.2008.02.061; PMID: 18395970
   PubMed Web of Science ®Google Scholar
• Segal NH, Saltz LB. Evolving treatment of advanced colon cancer. Annu Rev Med 2009; 60:207 - 19; http://dx.doi.org/10.1146/annurev.med.60.041807.132435; PMID: 19630571
   PubMed Web of Science ®Google Scholar
• Blume-Jensen P, Hunter T. Oncogenic kinase signaling. Nature 2001; 411:335 - 6; http://dx.doi.org/10.1038/35077225
   Web of Science ®Google Scholar
• Comes F, Matrone A, Lastella P, Nico B, Susca FC, Bagnulo R, et al. A novel cell type-specific role of p38α in the control of autophagy and cell death in colorectal cancer cells. Cell Death Differ 2007; 14:693 - 702; http://dx.doi.org/10.1038/sj.cdd.4402076; PMID: 17159917
   PubMed Web of Science ®Google Scholar
• Chiacchiera F, Grossi V, Cappellari M, Peserico A, Simonatto M, Germani A, et al. Blocking p38/ERK crosstalk affects colorectal cancer growth by inducing apoptosis in vitro and in preclinical mouse models. Cancer Lett 2012; 324:98 - 108; http://dx.doi.org/10.1016/j.canlet.2012.05.006; PMID: 22579651
   PubMed Web of Science ®Google Scholar
• Chiacchiera F, Matrone A, Ferrari E, Ingravallo G, Lo Sasso G, Murzilli S, et al. p38alpha blockade inhibits colorectal cancer growth in vivo by inducing a switch from HIF1alpha- to FoxO-dependent transcription. Cell Death Differ 2009; 16:1203 - 14; http://dx.doi.org/10.1038/cdd.2009.36; PMID: 19343039
   PubMed Web of Science ®Google Scholar
• Chiacchiera F, Simone C. Inhibition of p38alpha unveils an AMPK-FoxO3A axis linking autophagy to cancer-specific metabolism. Autophagy 2009; 5:1030 - 3; http://dx.doi.org/10.4161/auto.5.7.9252; PMID: 19587525
   PubMed Web of Science ®Google Scholar
• Chiacchiera F, Simone C. The AMPK-FoxO3A axis as a target for cancer treatment. Cell Cycle 2010; 9:1091 - 6; http://dx.doi.org/10.4161/cc.9.6.11035; PMID: 20190568
   PubMed Web of Science ®Google Scholar
• Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol 2005; 6:322 - 7; http://dx.doi.org/10.1016/S1470-2045(05)70168-6; PMID: 15863380
   PubMed Web of Science ®Google Scholar
• Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999; 5:810 - 6; http://dx.doi.org/10.1038/10533; PMID: 10395327
   PubMed Web of Science ®Google Scholar
• Wickenden JA, Jin H, Johnson M, Gillings AS, Newson C, Austin M, et al. Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM. Oncogene 2008; 27:7150 - 61; http://dx.doi.org/10.1038/onc.2008.335; PMID: 18806830
   PubMed Web of Science ®Google Scholar
• Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004; 22:4456 - 62; http://dx.doi.org/10.1200/JCO.2004.01.185; PMID: 15483017
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5:835 - 44; http://dx.doi.org/10.1038/nrd2130; PMID: 17016424
   PubMed Web of Science ®Google Scholar
• Namboodiri HV, Bukhtiyarova M, Ramcharan J, Karpusas M, Lee Y, Springman EB. Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases. Biochemistry 2010; 49:3611 - 8; http://dx.doi.org/10.1021/bi100070r; PMID: 20337484
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099 - 109; http://dx.doi.org/10.1158/0008-5472.CAN-04-1443; PMID: 15466206
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 7:3129 - 40; http://dx.doi.org/10.1158/1535-7163.MCT-08-0013; PMID: 18852116
   PubMed Web of Science ®Google Scholar
• Dal Lago L, D’Hondt V, Awada A. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist 2008; 13:845 - 58; http://dx.doi.org/10.1634/theoncologist.2007-0233; PMID: 18695262
   PubMed Web of Science ®Google Scholar
• Matrone A, Grossi V, Chiacchiera F, Fina E, Cappellari M, Caringella AM, et al. p38alpha is required for ovarian cancer cell metabolism and survival. Int J Gynecol Cancer 2010; 20:203 - 11; http://dx.doi.org/10.1111/IGC.0b013e3181c8ca12; PMID: 20169663
   PubMed Web of Science ®Google Scholar
• Gillissen B, Wendt J, Richter A, Richter A, Müer A, Overkamp T, et al. Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma. J Cell Biol 2010; 188:851 - 62; http://dx.doi.org/10.1083/jcb.200912070; PMID: 20308427
   PubMed Web of Science ®Google Scholar
• Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 2008; 4:151 - 75; PMID: 18188003
   PubMed Web of Science ®Google Scholar
• Filomia F, De Rienzo F, Menziani MC. Insights into MAPK p38alpha DFG flip mechanism by accelerated molecular dynamics. Bioorg Med Chem 2010; 18:6805 - 12; http://dx.doi.org/10.1016/j.bmc.2010.07.047; PMID: 20724167
   PubMed Web of Science ®Google Scholar
• Kufareva I, Abagyan R. Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. J Med Chem 2008; 51:7921 - 32; http://dx.doi.org/10.1021/jm8010299; PMID: 19053777
   PubMed Web of Science ®Google Scholar
• Carnero A. The PKB/AKT pathway in cancer. Curr Pharm Des 2010; 16:34 - 44; http://dx.doi.org/10.2174/138161210789941865; PMID: 20214616
   PubMed Web of Science ®Google Scholar
• Montagut C, Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 2009; 283:125 - 34; http://dx.doi.org/10.1016/j.canlet.2009.01.022; PMID: 19217204
   PubMed Web of Science ®Google Scholar
• Dar AC, Das TK, Shokat KM, Cagan RL. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature 2012; 486:80 - 4; http://dx.doi.org/10.1038/nature11127; PMID: 22678283
   PubMed Web of Science ®Google Scholar
• Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 2010; 10:130 - 7; http://dx.doi.org/10.1038/nrc2787; PMID: 20094047
   PubMed Web of Science ®Google Scholar
• Pierotti MA, Tamborini E, Negri T, Pricl S, Pilotti S. Targeted therapy in GIST: in silico modeling for prediction of resistance. Nat Rev Clin Oncol 2011; 8:161 - 70; http://dx.doi.org/10.1038/nrclinonc.2011.3; PMID: 21364689
   PubMed Web of Science ®Google Scholar
• Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006; 2:358 - 64; http://dx.doi.org/10.1038/nchembio799; PMID: 16783341
   PubMed Web of Science ®Google Scholar